CD19 Antibodies, Memorial Sloan Kettering, 18 Claims
Summary
The USPTO granted Patent US12612456B2 to Memorial Sloan Kettering Cancer Center on April 28, 2026, covering CD19 antibodies and methods of using the same for detecting and treating CD19-associated autoimmune diseases and cancers. The patent lists 18 claims and names Nai-Kong V. Cheung, Sayed Shahabuddin Hoseini, and Mahiuddin Ahmed as inventors. The application was filed on April 7, 2020, under Application No. 17602176.
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO granted Patent US12612456B2 to Memorial Sloan Kettering Cancer Center for CD19 antibodies and methods of use. The patent covers compositions that bind to CD19 protein and their application in detecting and treating CD19-associated autoimmune diseases and CD19-associated cancers. The patent contains 18 claims.
Parties interested in CD19-targeted antibody therapeutics should be aware that Memorial Sloan Kettering Cancer Center holds enforceable IP rights in this space. Researchers and developers working on CD19-targeted therapies should conduct freedom-to-operate analyses to assess potential licensing needs before commercial development.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CD19 antibodies and methods of using the same
Grant US12612456B2 Kind: B2 Apr 28, 2026
Assignee
Memorial Sloan Kettering Cancer Center
Inventors
Nai-Kong V. Cheung, Sayed Shahabuddin Hoseini, Mahiuddin Ahmed
Abstract
The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD 19 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD 19-associated autoimmune disease or a CD19-associated cancer in a subject in need thereof.
CPC Classifications
C07K 16/2896 C07K 2317/56 C07K 16/00 A61P 35/00 A61P 35/02 A61K 2039/505
Filing Date
2020-04-07
Application No.
17602176
Claims
18
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.